We will explore the potential for extending the application of the methodology developed in task 4.4.4 for assessing AI technologies and novel approaches in cancer screening tests across Europe. The aim is to apply the MAS-AI methodology adopted to the European context in 2-3 clinical use cases from participating countries. The inclusion criteria for the use cases is that they are built on or utilize state-of-the-art AI technology as a component in the national cancer screening programs in participating countries. By applying the model on specific European use cases, the aim is to assess the feasibility, acceptability and comprehensibility of the model in different countries across Europe and to validate the transferability of the model in the context of European cancer screening.
This task will be led by RSYD, Denmark, co-led by CPO, Italy and EMC, the Netherlands